ENGOT-EN3-NSGO/PALEO: A Randomized, Double-blind, Placebo-controlled, Phase II Trial of Palbociclib in Combination With Letrozole Versus Placebo in Combination With Letrozole for Patients With Estrogen Receptor Positive Advanced or Recurrent Endometrial Cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2017 Planned number of patients changed from 80 to 78.
- 01 Apr 2017 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.